{"entity":{"type":"insider","cik":"0001779479","url":"/insider/0001779479","json_url":"/insider/0001779479.json","name":"Rolph Timothy","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":56,"n_filings":31,"first":"2022-09-15","last":"2025-10-09","span_basis":"filed_date"},"name_variants":[{"name":"Rolph Timothy","source":"filing","n_filings":31,"first_seen":"2022-09-15","last_seen":"2025-10-09"}],"transactions":[{"id":4093182,"accession":"0001193125-25-236152","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-25-236152","line_url":"/filing/0001193125-25-236152","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":46.08011464,"price_display":"46.08","price_state":"stated","total_value":576001.433,"total_display":"576,001.43","total_whole":"576,001","shares_owned_after":167608.0,"shares_owned_after_display":"167,608","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-07","filed_date":"2025-10-09","scope":"insider","n_lines":2},{"id":4196169,"accession":"0000950170-25-114662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-114662","line_url":"/filing/0000950170-25-114662#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":553.0,"shares_display":"553","price_per_share":43.02,"price_display":"43.02","price_state":"stated","total_value":23790.06,"total_display":"23,790.06","total_whole":"23,790","shares_owned_after":166571.0,"shares_owned_after_display":"166,571","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-12","scope":"insider"},{"id":4517058,"accession":"0001779479-25-000007","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001779479-25-000007","line_url":"/filing/0001779479-25-000007","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":44.17092032,"price_display":"44.17","price_state":"stated","total_value":552136.504,"total_display":"552,136.50","total_whole":"552,137","shares_owned_after":167158.0,"shares_owned_after_display":"167,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-10","scope":"insider","n_lines":2},{"id":4027905,"accession":"0000950170-25-104623","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-104623","line_url":"/filing/0000950170-25-104623","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":49.30393584,"price_display":"49.30","price_state":"stated","total_value":616299.198,"total_display":"616,299.20","total_whole":"616,299","shares_owned_after":167124.0,"shares_owned_after_display":"167,124","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-05","filed_date":"2025-08-07","scope":"insider","n_lines":2},{"id":4714701,"accession":"0000950170-25-094882","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-094882","line_url":"/filing/0000950170-25-094882","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":51.0928708,"price_display":"51.09","price_state":"stated","total_value":638660.885,"total_display":"638,660.88","total_whole":"638,661","shares_owned_after":168990.0,"shares_owned_after_display":"168,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-07","filed_date":"2025-07-09","scope":"insider","n_lines":3},{"id":4714408,"accession":"0000950170-25-088638","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-088638","line_url":"/filing/0000950170-25-088638#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1129.0,"shares_display":"1,129","price_per_share":54.84,"price_display":"54.84","price_state":"stated","total_value":61914.36,"total_display":"61,914.36","total_whole":"61,914","shares_owned_after":166234.0,"shares_owned_after_display":"166,234","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-18","filed_date":"2025-06-20","scope":"insider"},{"id":4946865,"accession":"0000950170-25-085673","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-085673","line_url":"/filing/0000950170-25-085673#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2358.0,"shares_display":"2,358","price_per_share":53.996,"price_display":"54.00","price_state":"stated","total_value":127322.568,"total_display":"127,322.57","total_whole":"127,323","shares_owned_after":167363.0,"shares_owned_after_display":"167,363","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":4165600,"accession":"0000950170-25-083878","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-25-083878","line_url":"/filing/0000950170-25-083878#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":55.04,"price_display":"55.04","price_state":"stated","total_value":1376000.0,"total_display":"1,376,000.00","total_whole":"1,376,000","shares_owned_after":169721.0,"shares_owned_after_display":"169,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-06","filed_date":"2025-06-09","scope":"insider"},{"id":4165589,"accession":"0000950170-25-083878","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-083878","line_url":"/filing/0000950170-25-083878","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":53.490684,"price_display":"53.49","price_state":"stated","total_value":668633.55,"total_display":"668,633.55","total_whole":"668,634","shares_owned_after":172871.0,"shares_owned_after_display":"172,871","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-05","filed_date":"2025-06-09","scope":"insider","n_lines":2},{"id":4461863,"accession":"0000950170-25-067381","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-067381","line_url":"/filing/0000950170-25-067381","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":43.429088,"price_display":"43.43","price_state":"stated","total_value":542863.6,"total_display":"542,863.60","total_whole":"542,864","shares_owned_after":170021.0,"shares_owned_after_display":"170,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-06","filed_date":"2025-05-08","scope":"insider","n_lines":3},{"id":4946190,"accession":"0000950170-25-059449","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-059449","line_url":"/filing/0000950170-25-059449#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6250.0,"shares_display":"6,250","price_per_share":41.03,"price_display":"41.03","price_state":"stated","total_value":256437.5,"total_display":"256,437.50","total_whole":"256,438","shares_owned_after":169721.0,"shares_owned_after_display":"169,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-24","filed_date":"2025-04-28","scope":"insider"},{"id":4417605,"accession":"0000950170-25-052956","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-25-052956","line_url":"/filing/0000950170-25-052956","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6250.0,"shares_display":"6,250","price_per_share":35.88184,"price_display":"35.88","price_state":"stated","total_value":224261.5,"total_display":"224,261.50","total_whole":"224,262","shares_owned_after":170021.0,"shares_owned_after_display":"170,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-07","filed_date":"2025-04-10","scope":"insider","n_lines":4},{"id":4234983,"accession":"0000950170-25-039731","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-039731","line_url":"/filing/0000950170-25-039731#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":516.0,"shares_display":"516","price_per_share":44.88,"price_display":"44.88","price_state":"stated","total_value":23158.08,"total_display":"23,158.08","total_whole":"23,158","shares_owned_after":169721.0,"shares_owned_after_display":"169,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-12","filed_date":"2025-03-14","scope":"insider"},{"id":4834900,"accession":"0000950170-25-035709","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-035709","line_url":"/filing/0000950170-25-035709","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":44.52722704,"price_display":"44.53","price_state":"stated","total_value":556590.338,"total_display":"556,590.34","total_whole":"556,590","shares_owned_after":173399.0,"shares_owned_after_display":"173,399","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-05","filed_date":"2025-03-07","scope":"insider","n_lines":2},{"id":4872248,"accession":"0000950170-25-016493","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-016493","line_url":"/filing/0000950170-25-016493","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18750.0,"shares_display":"18,750","price_per_share":56.513581173333336,"price_display":"56.51","price_state":"stated","total_value":1059629.647,"total_display":"1,059,629.65","total_whole":"1,059,630","shares_owned_after":176140.0,"shares_owned_after_display":"176,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-05","filed_date":"2025-02-07","scope":"insider","n_lines":2},{"id":4710936,"accession":"0000950170-25-010707","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-25-010707","line_url":"/filing/0000950170-25-010707","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31250.0,"shares_display":"31,250","price_per_share":55.77466656,"price_display":"55.77","price_state":"stated","total_value":1742958.33,"total_display":"1,742,958.33","total_whole":"1,742,958","shares_owned_after":187675.0,"shares_owned_after_display":"187,675","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-29","scope":"insider","n_lines":3},{"id":2774303,"accession":"0000950170-24-138134","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-138134","line_url":"/filing/0000950170-24-138134#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3800.0,"shares_display":"3,800","price_per_share":31.098,"price_display":"31.10","price_state":"stated","total_value":118172.4,"total_display":"118,172.40","total_whole":"118,172","shares_owned_after":178337.0,"shares_owned_after_display":"178,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-17","filed_date":"2024-12-18","scope":"insider"},{"id":2243437,"accession":"0000950170-24-136025","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-136025","line_url":"/filing/0000950170-24-136025","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4818.0,"shares_display":"4,818","price_per_share":30.912042341220424,"price_display":"30.91","price_state":"stated","total_value":148934.22,"total_display":"148,934.22","total_whole":"148,934","shares_owned_after":178337.0,"shares_owned_after_display":"178,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider","n_lines":2},{"id":2082939,"accession":"0000950170-24-106458","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-106458","line_url":"/filing/0000950170-24-106458#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":537.0,"shares_display":"537","price_per_share":26.18,"price_display":"26.18","price_state":"stated","total_value":14058.66,"total_display":"14,058.66","total_whole":"14,059","shares_owned_after":180705.0,"shares_owned_after_display":"180,705","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-13","scope":"insider"},{"id":2388608,"accession":"0000950170-24-073185","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-073185","line_url":"/filing/0000950170-24-073185#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2380.0,"shares_display":"2,380","price_per_share":22.641,"price_display":"22.64","price_state":"stated","total_value":53885.58,"total_display":"53,885.58","total_whole":"53,886","shares_owned_after":180178.0,"shares_owned_after_display":"180,178","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-11","filed_date":"2024-06-13","scope":"insider"},{"id":2116074,"accession":"0000950170-24-032261","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-032261","line_url":"/filing/0000950170-24-032261#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":619.0,"shares_display":"619","price_per_share":28.33,"price_display":"28.33","price_state":"stated","total_value":17536.27,"total_display":"17,536.27","total_whole":"17,536","shares_owned_after":182558.0,"shares_owned_after_display":"182,558","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-15","scope":"insider"},{"id":8282490,"accession":"0000950170-23-071236","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-071236","line_url":"/filing/0000950170-23-071236#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":514.0,"shares_display":"514","price_per_share":20.76,"price_display":"20.76","price_state":"stated","total_value":10670.64,"total_display":"10,670.64","total_whole":"10,671","shares_owned_after":182672.0,"shares_owned_after_display":"182,672","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-14","filed_date":"2023-12-18","scope":"insider"},{"id":7857658,"accession":"0000950170-23-049764","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-049764","line_url":"/filing/0000950170-23-049764#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":531.0,"shares_display":"531","price_per_share":50.34,"price_display":"50.34","price_state":"stated","total_value":26730.54,"total_display":"26,730.54","total_whole":"26,731","shares_owned_after":150689.0,"shares_owned_after_display":"150,689","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-13","filed_date":"2023-09-25","scope":"insider"},{"id":8530270,"accession":"0000950170-23-029227","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-23-029227","line_url":"/filing/0000950170-23-029227","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":78200.0,"shares_display":"78,200","price_per_share":54.78345180051151,"price_display":"54.78","price_state":"stated","total_value":4284065.9308,"total_display":"4,284,065.93","total_whole":"4,284,066","shares_owned_after":180095.0,"shares_owned_after_display":"180,095","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-16","filed_date":"2023-06-21","scope":"insider","n_lines":3},{"id":8135758,"accession":"0000899243-23-015670","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-015670","line_url":"/filing/0000899243-23-015670#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":509.0,"shares_display":"509","price_per_share":55.16,"price_display":"55.16","price_state":"stated","total_value":28076.44,"total_display":"28,076.44","total_whole":"28,076","shares_owned_after":189420.0,"shares_owned_after_display":"189,420","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-13","filed_date":"2023-06-15","scope":"insider"},{"id":6319430,"accession":"0000899243-22-039574","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-039574","line_url":"/filing/0000899243-22-039574","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20316.0,"shares_display":"20,316","price_per_share":51.049356211852725,"price_display":"51.05","price_state":"stated","total_value":1037118.7208,"total_display":"1,037,118.72","total_whole":"1,037,119","shares_owned_after":190532.0,"shares_owned_after_display":"190,532","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-29","filed_date":"2022-12-30","scope":"insider","n_lines":2},{"id":6319421,"accession":"0000899243-22-039574","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-039574","line_url":"/filing/0000899243-22-039574#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700.0,"shares_display":"1,700","price_per_share":50.0038,"price_display":"50.00","price_state":"stated","total_value":85006.46,"total_display":"85,006.46","total_whole":"85,006","shares_owned_after":203032.0,"shares_owned_after_display":"203,032","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-28","filed_date":"2022-12-30","scope":"insider"},{"id":6589140,"accession":"0000899243-22-036055","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-036055","line_url":"/filing/0000899243-22-036055","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3947.0,"shares_display":"3,947","price_per_share":45.4683885989359,"price_display":"45.47","price_state":"stated","total_value":179463.7298,"total_display":"179,463.73","total_whole":"179,464","shares_owned_after":183937.0,"shares_owned_after_display":"183,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-16","filed_date":"2022-11-16","scope":"insider","n_lines":2},{"id":6589131,"accession":"0000899243-22-036055","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-036055","line_url":"/filing/0000899243-22-036055#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3138.0,"shares_display":"3,138","price_per_share":45.0423,"price_display":"45.04","price_state":"stated","total_value":141342.7374,"total_display":"141,342.74","total_whole":"141,343","shares_owned_after":187784.0,"shares_owned_after_display":"187,784","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-15","filed_date":"2022-11-16","scope":"insider"},{"id":6364942,"accession":"0000899243-22-034372","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-034372","line_url":"/filing/0000899243-22-034372#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779479","owner_name":"Rolph Timothy","owner_display_name":"Rolph Timothy","owner_url":"/insider/0001779479","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4762.0,"shares_display":"4,762","price_per_share":45.03,"price_display":"45.03","price_state":"stated","total_value":214432.86,"total_display":"214,432.86","total_whole":"214,433","shares_owned_after":190922.0,"shares_owned_after_display":"190,922","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-26","filed_date":"2022-10-27","scope":"insider"}],"collapsed":true,"next_cursor":"2022-10-26|6364942","ledger_fault":false,"count":{"value":56,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":56,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":56},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Officer (Chief Scientific Officer)","n_filings":31,"first_seen":"2022-09-15","last_seen":"2025-10-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001779479","retrieved_at":"2026-08-23T12:11:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}